Renovacor Company Profile

07:26 EDT 23rd August 2019 | BioPortfolio

News Articles [4 Associated News Articles listed on BioPortfolio]

Renovacor raises $11M to advance gene therapy for rare cardiomyopathy

With backing from its syndicate’s five investors, Renovacor is eyeing an IND submission.

Renovacor raises $11M to advance gene therapy research

Temple University spinout Renovacor gained $11 million from a Series A funding round, which the company will use to advance d -More- 

Renovacor raises $11M to advance gene therapy for dilated cardiomyopathy

Renovacor Closes $11 Million Series A Financing to Advance First Gene Therapy for a Rare Cardiovascular Disease

- Funding supports preclinical development through IND submission for its BAG3 gene therapy, the first gene replacement product for genetic forms of dilated cardiomyopathy - Company announces lead...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


More Information about "Renovacor" on BioPortfolio

We have published hundreds of Renovacor news stories on BioPortfolio along with dozens of Renovacor Clinical Trials and PubMed Articles about Renovacor for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Renovacor Companies in our database. You can also find out about relevant Renovacor Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record